Clinical Trial: A Phase I/IIa Clinical Study on the Safety and Efficacy of CD19-Targeted Genetically Modified Allogeneic Chimeric Antigen Receptor T Cell Injection (BRL-303) in the Treatment of Relapsed/Refractory Systemic Sclerosis (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase I/IIa Clinical Study on the Safety and Efficacy of CD19-Targeted Genetically Modified Allogeneic Chimeric Antigen Receptor T Cell Injection (BRL-303) in the Treatment of Relapsed/Refractory Systemic Sclerosis'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135527

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Xiangya Hospital Central South University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348960

Published by HT Digital Content Services with permission from Health Daily Digest....